By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DSG, Inc. 

Global Headquarters
325 Technology Drive
Malvern  Pennsylvania    U.S.A.
Phone: 484-913-0210 Fax: 484-913-0224


Company News
CeloNova BioSciences Release: FDA Approves NanoCoated Coronary Stent System Using DSG, Inc.’s eClinical Systems 3/23/2017 10:49:24 AM
DSG, Inc. Release: Company Accelerates Growth With Opening Of New Office In Bangalore, India 1/20/2017 7:51:45 AM
Orbus Therapeutics Selects DSG, Inc. For EDC And IWRS In Recurrent Anaplastic Astrocytoma Clinical Study 9/30/2016 7:43:23 AM
Company Profile For DSG, Inc. 5/6/2016 10:23:47 AM
Supernus Pharmaceuticals (SUPN) Selects DSG, Inc. For EDC And IWRS In Phase III Clinical Studies On Impulsive Aggression In Pediatric Patients Treated For Attention Deficit/Hyperactivity Disorder (ADHD) 4/1/2016 10:32:01 AM
DSG, Inc. Partners With Soligenix (SNGX) To Battle Cutaneous T-Cell Lymphoma 4/7/2015 10:41:14 AM
Drug Approved In Pivotal Studies Using DSG, Inc.’s Fully Electronic Source Data 3/3/2015 1:07:52 PM
DSG, Inc. And Opko Health, Inc. Enter Into Enterprise Licensing Agreement For Fully Integrated EDC, IWRS, Safety, And Trial Management Solution 11/4/2014 10:38:33 AM
Romark Laboratories, L.C. Selects DSG, Inc. For Influenza Study 3/11/2014 8:49:08 AM
Milo Biotechnology Announces DSG, Inc. Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy 12/12/2012 9:46:02 AM